Summit Materials to combine with Cementos Argos' U.S. business in a cash and stock deal valued at about $3.2 billion
Shares of Summit Materials Inc. (SUM) rallied 2.4% in premarket trading Thursday, after the cement maker announced an agreement to combine with Argos North America Corp. (Argos USA), the U.S. operations of Colombia-based Cementos Argos S.A. in a cash and stock deal valued at about $3.2 billion. Under terms of the deal, Summit will pay Cementos Argos $1.2 billion in cash and 54.7 million of its shares, which based on Wednesday's closing price of $36.00 would be valued at about $1.97 billion. The company targets synergies of more than $100 million a year from the combination. "The transaction will extend our geographic reach into high growth markets, creating a leading cement enterprise nationwide, and bring together two talent-rich organizations to innovate and deliver value-added solutions for our customers," Summit Chief Executive Anne Noonan said. Summit's stock has run up 26.8% year to date through Wednesday, while the S&P 500 has advanced 16.3%.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-07-23 0739ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?